Triple-negative breast cancer--current status and future directions (Q37630082)

21 August 2017

1 reference

title

Triple-negative breast cancer--current status and future directions (English)

1 reference

triple-negative breast cancer

21 August 2017

0 references

author name string

O Gluz

1

1 reference

21 August 2017

C Liedtke

2

1 reference

21 August 2017

N Gottschalk

3

1 reference

21 August 2017

L Pusztai

4

1 reference

21 August 2017

U Nitz

5

1 reference

21 August 2017

N Harbeck

6

1 reference

21 August 2017

9 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

20

1 reference

21 August 2017

12

1 reference

21 August 2017

1913-1927

1 reference

Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status

21 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Generation of a functional mammary gland from a single stem cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

The CD44+/CD24- phenotype is enriched in basal-like breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

How basal are triple-negative breast cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Typical medullary breast carcinomas have a basal/myoepithelial phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Risk factors for triple-negative breast cancer in women under the age of 45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Epidemiology of basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Differences in risk factors for breast cancer molecular subtypes in a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

The epidemiology of triple-negative breast cancer, including race

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Triple-negative breast cancers are increased in black women regardless of age or body mass index

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Triple-negative breast cancer: correlation between MR imaging and pathologic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Basal-like breast carcinomas: clinical outcome and response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Pattern of metastatic spread in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Impact of triple negative phenotype on breast cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Survival among women with triple receptor-negative breast cancer and brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Integrated profiling of basal and luminal breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Cell-type-specific responses to chemotherapeutics in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Genomic grade index is associated with response to chemotherapy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

The role of BRCA1 in the cellular response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Platinum-based chemotherapy in triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Triple-negative breast cancer: therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

The sequence of human caveolin reveals identity with VIP21, a component of transport vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Can women with early-stage breast cancer make an informed decision for mastectomy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP492

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP492

1 reference

21 August 2017

1 reference